Brought to you by 
Merck acquires GlycoFi for $400mm
25 Feb 2011
Executive Summary
Impressed with results of a collaboration formed by the parties last year, Merck has decided to acquire glycoprotein therapeutics developer GlycoFi for $400mm cash, gaining access to technology to develop biosimilars.
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Synthesis Technologies, Production Processes
-
Large Molecule
- Antibodies
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Payment Includes Cash
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Merck acquires GlycoFi for $400mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice